• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment.
    公开号:EP3708568A1
    申请号:EP18898008.0
    申请日:2018-12-25
    公开日:2020-09-16
    发明作者:Guangwei He；Zhaoxing CHU；Qinlong XU；Feng Li；Weizhong Liu；Jiajia MO；Yan Zhao
    申请人:Hefei Amvite Pharmaceutical Co Ltd；Hefei Industrial Pharmaceutical Institute Co Ltd；
    IPC主号:A61P29-00
    专利说明:
    [0001] The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4, a preparation method thereof and a pharmaceutical composition comprising the compound, and a therapeutic use thereof. Background
    [0002] Inflammation is a common pathological process. Traumatic infections on the body surface and most common and frequently-occurring diseases of various organs (such as furuncle, carbuncle, pneumonia, hepatitis, nephritis, etc.) are inflammatory diseases. [Cruz-Migoni S, Caamaño J. Fat-Associated Lymphoid Clusters in Inflammation and Immunity[J]. Front Immunol. 2016, 7: 612]. Currently, the main clinical methods for treating inflammatory diseases are using topical or systemic hormonal drugs, which have obvious side effects. Searching and discovering a non-hormonal drug with stronger anti-inflammatory activity has been the goal of drug developers.
    [0003] Phosphodiesterase 4 (PDE4) is a major PDE expressed in neutrophils and T cells, suggesting that a PDE4 inhibitor can effectively control inflammation. Inhibiting PDE4 in inflammatory cells can affect various specific responses, such as the production or release of proinflammatory mediators including cytokines and reactive oxygen species, and has significant effects in the treatment of asthma, COPD, inflammatory bowel disease, atopic dermatitis, psoriasis and rheumatoid arthritis. However, PDE4 isoenzyme inhibitors currently in clinical use, such as rolipram, piclamilast, CDP-840 and avery etc., all have side effects such as vomiting, liver toxicity, and skin irritation, with either failure in drug clinical trials or limitation in the clinical application. It is still necessary to find a new highly effective and low toxicity phosphodiesterase-4 inhibitor for the treatment of inflammatory diseases.
    [0004] US20060234981 discloses a class of boron-containing small molecule compound 1 (Crisaborole), which inhibits PDE4 enzyme and has anti-inflammatory activity. I have previously published a compound 2 (Y5) in the patent CN106831840 , which showed superior anti-inflammatory activity to Crisaborole. The disclosure designs and synthesizes a series of new compounds, and it is unexpectedly found that these compounds show significantly better effects and improved use than Crisaborole and Y5. Summary
    [0005] Based on the previous studies, the disclosure designs and synthesizes a class of compounds having a general formula (I). The pharmacodynamic test proves that the compound of the disclosure may inhibit the activity of the phosphodiesterase 4, and have a use in preventing and treating inflammation-related diseases.
    [0006] The disclosure is described in detail below.
    [0007] The disclosure discloses a compound having a general formula (I):
    [0008] Preferably, the disclosure includes a compound with the following structures:
    [0009] Preferably, the disclosure further includes the following compounds:
    [0010] Some preferred compounds are as follows: Compound No. Structure Compound No. Structure PD-1
    [0011] The compound and a pharmaceutically acceptable salt thereof of the disclosure are selected from salts formed from alkali metals or alkaline earth metals, amino acids or basic compounds containing amino groups, or salts formed from pharmaceutically acceptable inorganic or organic acids, preferably are a potassium salt, a sodium salt, an ammonium salt, a hydrochloride, a sulfuric acid, a phosphate salt, a hydrobromic acid, a maleic acid, a fumaric acid, a citric acid, a methanesulfonic acid, a p-toluenesulfonic acid, a tartaric acid or an acetate.
    [0012] An application of the pharmaceutical composition of the compound or pharmaceutically acceptable salt thereof and the pharmaceutically acceptable carrier according to the disclosure in preparing a drug for treating inflammatory diseases.
    [0013] In a pharmaceutical composition including the compound according to the disclosure for treating and preventing inflammatory diseases, a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier are included. The pharmaceutical composition may be in the form of a pharmaceutically conventional preparation such as an ordinary tablet or capsule, a sustained-release tablet or capsule, a controlled release tablet or capsule, a granule, an oral liquid, a syrup, a suppository, a transdermal preparation, an injection, etc.
    [0014] The preparation method of the compound of the disclosure includes:
    [0015] The preparation of other compounds may refer to the above method.
    [0016] For biological evaluation, the beneficial effects of the compounds of the disclosure are illustrated by the following experimental data.
    [0017] The compound of the disclosure has an inhibiting effect on PDE4 enzyme.
    [0018] The PDE4A enzyme expressed from baculovirus is labeled with N-terminal GST from Sf9 insect cells. A specified PDE4A enzyme and 1 mM cAMP are added to the newly prepared pH 7.5 Tris buffer, the enzyme solution is transferred into reaction wells, and the compound is sonicated in DMSO and then added to the enzyme solution for culturing for 10 minutes at room temperature; the substrate solution is poured into the reaction wells to initiate the reaction and cultured at room temperature for 1 hour, and a detection tracer (AMP2/GMP2 AlexaFluor 633 Tracer) and an antibody (Transcreener® AMP2/GMP2 Antibody) are added to stop the reaction for culturing for 90 minutes with gentle mixing. The fluorescence polarization is measured at Ex/Em 620/688, and the test objects are tested at concentrations of 1, 0.1, and 0.01 mM. When the enzyme activity is less than 50%, it is considered to significantly inhibit the activity.
    [0019] The experimental results are shown in Table 1 below. Table 1 Inhibition of the compound of the disclosure on the activity of PDE4 enzyme Compound No. Enzyme activity 1 µM 0.1 µM 0.01 µM Crisaborole 11.03±0.52 35.17±3.35 78.02±5.02 Y5 5.56±0.28** 15.32±1.30** 61.31±3.18*PD-1 3.74±0.71**# 5.45±1.06**## 18.79±3.23**##PD-2 2.75:t0.51**# 3.80±0.76**## 7.42±2.11**##PD-3 1.98±0.47**# 4.94±1.56**## 17.29±1.19**##PD-4 1.95±0.18**## 2.49±0.75**## 6.17±0.34**##PD-5 3.46±1.18**# 7.27±1.78**# 9.01±2.02**##PD-6 0.32±0.13**## 0.60±0.10**## 0.90±0.23**##PD-7 1.12±0.99**## 1.83±0.41**## 6.41±0.32**##PD-8 1.21±0.17**## 2.25±1.19**## 4.36±0.59**##PD-9 0.99±0.85**## 1.92±0.39**## 3.41±0.45**##PD-10 1.55±0.67**## 2.45±0.32**## 10.79±1.60**##PD-11 1.70±0.43**## 5.85±0.72**## 10.12±1.93**##PD-12 3.46±1.12**# 6.20±1.23**# 22.09±0.57**##PD-13 1.44±0.40**## 8.68±0.89**# 21.73±1.51**##PD-14 0.15±0.10**## 1.26±1.17**## 3.57±1.08**##PD-15 1.08±0.40**## 0.54±0.50**## 2.09±0.99**##PD-16 0.21±0.57**## 0.45±0.30**## 1.05±1.26**##PD-17 0.77±0.39**## 1.89±0.60**## 4.17±0.99**##PD-18 0.13±0.06**## 0.46±0.35**## 1.52±0.44**##PD-19 0.54±0.47**## 1.56±0.48**## 4.22±0.86**##PD-20 1.78±0.50**## 3.64±0.48**## 6.13±0.93**##PD-21 0.28±0.14**## 0.33±0.23**## 1.64±0.55**##PD-22 1.78±0.63**## 3.06±0.27**## 7.16±1.04**##PD-23 2.45±0.76**## 4.51±0.94**## 9.26±0.73**##PD-24 2.64±0.56**# 7.31±1.16**# 9.17±1.00**##PD-25 2.27±0.74**## 1.95±1.18**## 7.17±0.64**##PD-26 2.04±0.24**## 7.23±1.83**# 12.79±1.82**##PD-27 2.69±1.77**# 9.49±1.59**# 12.93±1.86**##PD-28 2.10±0.93**## 4.42±0.64**## 9.14±0.89**## (Compared with Crisaborole, *P<0.05, **P<0.01; compared with Y5, #P<0.01, ##P<0.01)
    [0020] By testing the inhibition of the compound of the disclosure on the activity of the PDE4 enzyme, it is found that the compounds of the disclosure are superior to Crisaborole and Y5 in inhibiting the activity of the PDE4 enzyme at various concentrations, wherein the compounds PD-4 to PD-9, PD-14 to PD-25, and PD-28 inhibit the PDE4 enzyme by more than 90% at three concentrations. Compounds of the disclosure on DNCB-induced dermatitis mouse model
    [0021] After female BALB/C mice are selected, each weighing 18-22g, for animal adaptive breeding for 7 days, these are randomly divided into a blank group, a model group, a positive drug Crisaborole group, a hexadecadrol group, and compound groups, with 8 in each group. Except for the mice in the blank group, the remaining mice are applied with 100 µL of a 1% DNCB solution [acetone: olive oil = 4: 1 (V/V)] on the skin of the back of the shaved mice, and applied continuously for 3 days once a day. Then, dosing treatment starts 4 days after the mice are housed, and the test drug is applied to the back of each group of animals, wherein animals in the blank group and the model group are applied with a corresponding solvent, the positive drug Crisaborole group and hexadecadrol group are applied with 50 mg/mL of a corresponding drug, and the administration group is applied with 50 mg/mL of a corresponding compound, with 100 µL for each mouse; after application of 4 hours, 0.5% DNCB solution is applied for secondary challenge, and repeated administration and challenge treatment are performed 11 times, once a day. 24 hours after the last administration, the animals are sacrificed, and the back skins (1×0.4cm2) are taken and fixed in 10% formalin buffer to make pathological sections and perform HE staining; then, the epidermal and dermal layers are observed under a 100x electron microscope, and 5 areas are selected for detection of and recording the skin thickness, and then the average value is taken to represent the final thicknesses of the epidermal layer and dermal layer, respectively.
    [0022] From the results, it can be known that the compound of the disclosure, hexadecadrol, Crisaborole, and compound Y5 may significantly reduce the thicknesses of the epidermal layer and dermal layer of DNCB-induced atopic dermatitis mice (P <0.01); specifically, the results are shown in Table 2: Table 2 Effects of the compound of the disclosure on the thickness of skin of DNCB-induced atopic dermatitis mice (Mean±SD, n=8) Groups Dose (mg/mL) Epidermal thickness (µm) Dermis thickness (µm) Blank - 48.93±7.63 194.70±20.55 Model - 137.76±10.75ΔΔ 500.71±28.96ΔΔhexadecadrol 50 72.14±10.58**aa 377.32±22.05**aaCrisaborole 50 105.26±11.35** 455.14±27.27**Y5 50 90.14±8.98**# 415.08±25.00**##PD-1 50 75.64±7.86**##aa 385.26±20.17**##aPD-2 50 100.26±11.35** 439.76±30.02**PD-3 50 98.74±9.63** 420.80±30.55**#PD-4 50 70.42±9.24**##aa 375.06±20.41**##aaPD-5 50 106.74±15.14** 440.12±23.22**PD-6 50 70.87114.43**##aa 380.15±22.54**##aaPD-7 50 68.21±7.66**##aa 370.11 ±24.60**##aaPD-8 50 76.58±8.79**##aa 385.17±28.85**##aPD-9 50 97.25±10.43** 413.25±31.50**#PD-10 50 92.17±9.94**# 406.74±29.54**##PD-11 50 95.37±8.75** 443.17±33.40**PD-12 50 72.15±8.57**#aa 362.44±25.78**##aaPD-13 50 100.23±11.62** 450.26±25.55**PD-14 50 75.24±7.98**##aa 365.40±21.95**##aaPD-15 50 74.28±8.26**##aa 376.62±23.73**##aaPD-16 50 78.64±9.75**##a 388.46±24.06**##aPD-17 50 80.76±10.51**## 380.74±20.15**##aaPD-18 50 90.35±11.20**# 436.16±35.42**PD-19 50 96.05±9.75** 441.12±30.17**PD-20 50 98.74±10.55** 438.14±29.71**PD-21 50 70.62±7.12**##aa 383.34±24.40**##aPD-22 50 103.45±11.74** 447.77±33.37**PD-23 50 97.34±8.36** 435.56±27.08**PD-24 50 91.17±9.03**# 420.33±24.75**#PD-25 50 87.77±10.58**# 412.42±26.74**#PD-26 50 83.94±7.63**# 408.97±23.06**##PD-27 50 97.73±8.95** 430.05±27.90**PD-28 50 70.51±12.45** 352.69±30.77**aa (Note: ΔP<0.05, ΔΔP<0.01, vs. blank group; *P<0.05, **P<0.01, vs. moel group, #P<0.05, ##P <0.01, vs. Crisaborole group; aP<0.05, aaP<0.01, coupound group and Y5 group)
    [0023] Compared with Crisaborole, the compounds PD-1, PD-4, PD-6, PD-7, PD-8, PD-10, PD-12, PD-14, PD-15, PD-16, PD-17, PD-21, PD -29, PD-30 may significantly reduce the thickness of the epidermis (P0.01), and PD-9, PD-24, PD-25, PD-26, PD-31, PD-32, PD-33, and compound Y5 may significantly reduce the thickness of the epidermis of the dermatitis mice (P0.05); the compounds PD-1, PD-4, PD-6, PD-7, PD-8, PD-10, PD-12, PD-14, PD-15, PD-16, PD-17, PD-21, PD-26, PD-29, PD-30, PD-31, PD-33, and the compound Y5 may significantly reduce the thickness of the dermis of dermatitis mice (P 0.01), and PD-3, PD-9, PD-24, PD-25, PD-32 may significantly reduce the thickness of the dermis of dermatitis mice (P0.05).
    [0024] Compared with the compound Y5, the compounds PD-1, PD-4, PD-6, PD-7, PD-8, PD-12, PD-14, PD-15, PD-21, PD -29 may significantly reduce the thickness of the epidermis (P0.01), and the compound PD-16 may significantly reduce the thickness of the epidermis (P<0.05); the compounds PD-4, PD-6, PD-7, PD-12, PD-14, PD-15, PD-17, PD-29 may significantly reduce the thickness of the dermis of dermatitis mice (P0.01), and PD-1, PD-8, PD-16, PD-21, PD-33 may significantly reduce the thickness of the dermis of dermatitis mice (P0.05).
    [0025] This suggests that the compound of the disclosure has a better anti-atopic dermatitis effect, and some compounds have better effects on the activity than Crisaborole and the compound Y5, thereby having good development prospects. DESCRIPTION OF EMBODIMENTSEmbodiment 1Preparation of PD-1Step 1 Preparation of an intermediate 2
    [0026]
    [0027] 50mL single-necked flask is charged with 1 (4.5g, 21.7mmol) and methyl iodide (4.58g, 32.55mmol), and 30mL DMF is added to dissolve. Then, potassium carbonate (6.03g, 43.4mmol) is added to stir at 100 °C for 2h until the reaction is completed through TLC detection, and then extracted with ethyl acetate, washed with saturated brine three times; the organic layer is dried, filtered, and concentrated, so as to obtain 4.2 g of a product with a yield of 87.5%. Step 2 Preparation of an intermediate 3
    [0028]
    [0029] 50mL single-necked flask is charged with 2 (4.2g, 20mmol) and 2-bromo-5hydroxybenzaldehyde (4g, 20mmol), and 50mL DMF is added to dissolve. Then, potassium carbonate (2.56g, 8mmol) is added to stir at 100 °C overnight under nitrogen until the reaction is completed through TLC detection, and then extracted with ethyl acetate, washed with saturated brine three times; the organic layer is dried, filtered, and concentrated, so as to obtain 1.5g of a product with a yield of 20% through column chromatography. Step 3 Preparation of an intermediate 4
    [0030]
    [0031] 50mL single-necked flask is charged with 3 (1.46g, 3.79mmol) and boronic acid pinacol ester (1.16g, 4.55mmol), and 20mL dioxane is added to dissolve. Then, potassium acetate (1.3g, 7.58mmol) and palladium reagent (277mg, 0.38mmol) are added to stir at 100 °C for 2 hours under nitrogen until the reaction is completed through TLC detection, and then extracted with ethyl acetate, washed with saturated brine three times; the organic layer is dried, filtered, and concentrated, so as to obtain 1.6g of a product with a yield of 97% through column chromatography. Step 4 Preparation of PD-1
    [0032]
    [0033] 50mL single-necked flask is charged with 4 (1.6g, 3.79mmol), 20ml methanol is added to dissolve, and sodium borohydride (168mg, 4.55mmol) is added slowly, to stir for 0.5h at room temperature. Then, 3M hydrochloric acid is added until a white solid precipitates, and then the reaction is continued for 2 hours, followed by suction filtration, washing three times, and drying, so as to obtain the product PD1 (0.8g, 63%). 1HNMR 400MHz(DMSO-d6 ) δ: 9.20-9.22(m, 2H), 8.10-8.12(m, 1H), 7.74-7.90(m, 3H), 7.44- 7.46(s, 1H), 7.32(d, 1H), 7.22-7.25(m, 1H), 5.01 (s, 2H), 3.96 (s,3H). Embodiment 2Synthesis of PD-2
    [0034] Referring to the method of Embodiment 1, 2-chloroquinoline-5-carboxylic acid is used as a raw material to prepare the PD-2 (70 mg, yield 13%). 1HNMR 400MHz (DMSO-d6 ) δ: 13.42(s, 1H)9.33-9.35(d, 1H), 9.22(s, 1H), 8.08-8.14(m, 1H), 7.81-7.88 (m, 2H), 7.73-7.77(m, 1H), 7.42-7.44(d, 1H), 7.32(s, 1H), 7.23- 7.25(m, 1H), 5.02(s, 2H). Embodiment 3Synthesis of PD-3
    [0035] Referring to the method of Embodiment 1, 2-chloroquinoline-5-carboxylic acid ethyl ester is used as a raw material to prepare the PD-3 (70 mg, yield 13%), 1HNMR 400MHz(DMSO-d6 ) δ: 9.20-9.22(m, 2H), 8.11-8.14(d,1H), 7.74-7.90(m,3H), 7.44-7.46(d, 1H), 7.32(s, 1H), 7.23-7.25(m, 1H), 5.01(s, 2H), 4.41-4.46(m, 2H), 1.38-1.42(m, 3H). Embodiment 4Synthesis of Compound PD-4
    [0036] Referring to the method of Embodiment 1, 2-chloro-6-cyanoquinoline is used as a raw material to prepare the PD-4 (56mg, 10%). 1HNMR 400MHz(DMSO-d6 ) δ: 9.24(s, 1H), 8.86 (s,1H), 8.53-8.55(d, 1H), 7.94-7.97(m, 1H), 7.82-7.84(d, 1H), 7.75-7.77(d, 1H), 7.46-7.48(d, 1H), 7.34(s, 1H), 7.24-7.26(d, 1H), 5.03(s, 2H). Embodiment 5Synthesis of PD-5
    [0037] Referring to the method of Embodiment 1, 2-chloroquinoline-4-carboxylate is used as a raw material to prepare the PD-5 (34.0 mg, 62.8%). 1HNMR 400MHz (DMSO-d6 ) δ: 9.22 (s, 1 H), 8.49 (d, J=8.28 Hz, 1 H), 7.82 (d, J=7.78 Hz, 1 H), 7.71 - 7.77(m, 2 H), 7.67 (s, 1 H), 7.56 -7.63 (m, 1 H), 7.33 (s, 1 H), 7.25 (dd, J=8.03, 1.51 Hz, 1 H), 5.02 (s, 2 H), 4.00 (s, 3 H). Embodiment 6Synthesis of Compound PD-6
    [0038] Referring to the method of Embodiment 1, 2-chloro-6-trifluoromethylquinoline is used as a raw material to prepare the PD-6 (104mg, 77.6%). 1HNMR 400MHz(DMSO-d6 ) δ: 9.24(s,1 H), 8.63-8.65(d, 1H), 8.49(s, 1H), 7.90-7.93 (m, 1H), 7.81-7.84(m, 1H), 7.46-7.48(d, 1H), 7.34(s, 1H), 7.24-7.27(m, 1H), 5.03(s, 2H). Embodiment 7Synthesis of Compound PD-7
    [0039] Referring to the method of Embodiment 1, 2-chloro-5-trifluoromethylquinoline is used as a raw material to prepare the PD-7 (105.0 mg, 59.9%). 1HNMR 400MHz(DMSO-d6 ) δ: 9.23 (s, 1 H), 8.54 (d, J=9.03 Hz, 1 H), 7.93-8.00 (m, 2 H), 7.79 - 7.86 (m, 2 H), 7.52 (d, J=9.29 Hz, 1 H), 7.35 (s, 1 H), 7.26 (d, J= 7.78 Hz, 1 H), 5.03 (s, 2 H). Embodiment 8
    [0040] Referring to the method of Embodiment 1,2,7-chloro-5-trifluoromethylquinoline is used as a raw material to prepare the PD-8 (33.5 mg, 39.9%). 1HNMR 400MHz(DMSO-d 6) δ: 9.23 (s, 1 H), 8.54 (d, J=9.03 Hz, 1 H), 7.93-8.00 (m, 2 H), 7.79 - 7.86 (m, 2 H), 7.52 (d, J=9.29 Hz, 1 H), 7.35 (s, 1 H), 7.26 (d, J= 7.78 Hz, 1 H), 5.03 (s, 2 H). Embodiment 9Synthesis of Compound PD-9
    [0041] Referring to the method of Embodiment 1, 2-chloro-4-trifluoromethyl-6-cyano-quinoline is used as a raw material to prepare the PD-9 (87 mg, 48%). 1HNMR 400MHz (DMSO-d6 ) δ: 9.27(s, 1H), 8.49 (s, 1H), 8.12-8.14(d, 1H), 7.99(s, 1H), 7.84-7.92(m, 2H), 7.40(s, 1H), 7.30-7.32(m, 1H), 5.04(s, 2H). Embodiment 10Synthesis of PD-10
    [0042] Referring to the method of Embodiment 1, 2-chloroquinoline-6-carboxylic acid methyl ester is used as a raw material to prepare the PD-12 (43 mg, 41%). 1H NMR (400 MHz, DMSO) δ 9.22 (s, 1H), 8.70 - 8.58 (m, 2H), 8.12 (dd, J = 8.8, 1.7 Hz, 1H), 7.82 (d, J = 7.9 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 8.8 Hz, 1H), 7.33 (s, 1H), 7.24 (d, J = 8.0 Hz, 1H), 5.02 (s, 2H), 3.91 (s, 3H). Embodiment 11Synthesis of PD-11
    [0043] Referring to the method of Embodiment 1, 2-chloroquinoline-5-amide is used as a raw material to prepare the PD-13 (37 mg, 32%). 1H NMR (400 MHz, DMSO) δ 9.24 (s, 1H), 8.83 (d, J = 9.1 Hz, 1H), 8.12 (s, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.76 - 7.59 (m, 4H), 7.40 - 7.29 (m, 2H), 7.23 (d, J = 7.9 Hz, 1H), 5.02 (s, 2H). Embodiment 12Synthesis of PD-12
    [0044] Referring to the method of Embodiment 1, 2-chloro-5-acetylquinoline is used as a raw material to prepare the PD-12 (35 mg, 31%). 1H NMR (400 MHz, DMSO) δ 9.21 (s, 1H), 9.07 (d, J = 9.2 Hz, 1H), 8.15 (dd, J = 7.2, 1.2 Hz, 1H), 7.79 (dd, J = 12.3, 7.8 Hz, 3H), 7.40 (d, J = 9.3 Hz, 1H), 7.30 (d, J = 1.4 Hz, 1H), 7.22 (dd, J = 8.0, 2.0 Hz, 1H), 5.01 (s, 2H), 2.74 (s, 3H). Embodiment 13Synthesis of PD-13
    [0045] Referring to the method of Embodiment 1, 2-chloro-6-amidoquinoline is used as a raw material to prepare the PD-13 (55 mg, 45%). 1H NMR (400 MHz, DMSO) δ 9.22 (s, 1H), 8.51 (d, J = 8.8 Hz, 2H), 8.12 (d, J = 10.3 Hz, 2H), 7.83 (d, J = 7.9 Hz, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.48 (s, 1H), 7.40 - 7.29 (m, 2H), 7.24 (d, J = 9.1 Hz, 1H), 5.03 (s, 2H). Embodiment 14Synthesis of PD-14
    [0046] Referring to the method of Embodiment 1, 2-chloro-6-acetylquinoline is used as a raw material to prepare the PD-14 (60 mg, 51%). 1H NMR (400 MHz, DMSO) δ 9.23 (s, 1H), 8.71 (d, J = 1.9 Hz, 1H), 8.62 (d, J = 8.8 Hz, 1H), 8.14 (dd, J = 8.8, 2.0 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 7.34 (d, J = 1.4 Hz, 1H), 7.25 (dd, J = 7.9, 2.0 Hz, 1H), 5.03 (s, 2H), 2.70 (s, 3H). Embodiment 15Synthesis of PD-15
    [0047] According to the method of Embodiment 1, 2,7-dichloro-6-trifluoromethylquinoline is used as a raw material to prepare the PD-15 (35 mg, 33.2%). 1HNMR 400MHz(DMSO-d6 ) δ: 9.27(s, 1H), 8.01 (d, J=8.8Hz, 1H), 7.84(d, J=7.9Hz, 1H), 7.64(d, J=8.9Hz, 1H), 7.35 (m,2H), 6.97 (d, J=7.9Hz, 1 H), 6.48(d, J=8.0Hz, 1H), 5.03(s, 2H). Embodiment 16Synthesis of PD-16
    [0048] According to the method of Embodiment 1, 2,7-dichloro-6-cyanoquinoline is used as a raw material to prepare the PD-16 (57 mg, 38%). 1H NMR (400 MHz, DMSO) δ 9.24 (s, 1H), 8.76 (s, 1H), 8.54 (d, J = 8.9 Hz, 1H), 7.94 (s, 1H), 7.82 (d, J = 7.9 Hz, 1H), 7.48 (d, J = 8.9 Hz, 1H), 7.34 (s, 1H), 7.25 (dd, J = 8.0, 2.0 Hz, 1H), 5.02 (s, 2H). Embodiment 17Synthesis of PD-17
    [0049] According to the method of Embodiment 1, 2-chloro-4,6-trifluoromethylquinoline is used as a raw material to prepare the PD-17 (57 mg, 38%). 1H NMR (400 MHz, DMSO) δ 9.21(s, 1H), 8.76-8.73 (m, 1H), 8.54 (d, J = 8.9 Hz, 1H), 7.94 (s, 1H), 7.82-7.73 (m, 1H), 7.43 (d, J = 8.9 Hz, 1H), 7.30 (s, 1H), 7.19 (dd, J = 8.0, 2.0 Hz, 1H), 5.02 (s, 2H). Embodiment 18Synthesis of PD-18
    [0050] According to the method of Embodiment 1, 2-chloro-4-trifluoromethylquinoline-6-carboxylic acid methyl ester is used as a raw material to prepare the PD-18 (37 mg, 38%). 1H NMR (400 MHz, DMSO) δ 9.11 (s, 1H), 8.46 (s, 1H), 8.10 (d, J = 8.8 Hz, 1H), 7.77 (s, 1H), 7.72 - 7.65 (m, 2H), 7.15 (d, J = 8.0 Hz, 1H), 4.89 (s, 2H), 3.79 (s, 3H). Embodiment 19Synthesis of PD-19
    [0051] According to the method of Embodiment 1, 2-chloro-4-trifluoromethyl-6-acetylquinolineis used as a raw material to prepare the PD-19 (107 mg, 68%). 1H NMR (400 MHz, DMSO) δ 9.26 (s, 1H), 8.54 (s, 1H), 8.30 (d, J = 8.8 Hz, 1H), 7.95 - 7.82 (m, 3H), 7.40 (s, 1H), 7.31 (dd, J = 8.0, 1.4 Hz, 1H), 5.05 (s, 2H), 2.72 (s, 3H). Embodiment 20Synthesis of PD-20
    [0052] According to the method of Embodiment 1, 2-chloro-4-fluoroquinoline-6-carboxylic acid methyl ester is used as a raw material to prepare the PD-20 (43 mg, 41%). 1HNMR 400MHz(DMSO-d6 ) δ: 9.30(s, 1H), 8.06-8.08 (d, 1H), 7.81-7.84(d, 1H), 7.62-7.64(d, 1H), 7.28-7.34 (m, 2H), 6.97-6.99(m, 2H), 5.04(s, 2H), 3.45 (s, 3H). Embodiment 21Synthesis of PD-21
    [0053] According to the method of Embodiment 1, 2-chloro-4-fluoro-6-trifluoromethylquinoline is used as a raw material to prepare the PD-21 (67 mg, 48%). 1HNMR 400MHz(DMSO-d6 ) δ: 9.26(s, 1H), 8.03 (d, J=8.8Hz, 1H), 7.81-7.84(m, 2H), 7.68-7.63(m, 1H), 7.28-7.34 (m, 2H), 6.48(d, J=8.0Hz, 1H), 5.03(m, 1H). Embodiment 22Synthesis of PD-22
    [0054] According to the method of Embodiment 1, 2-chloro-4-fluoro-6-cyanoquinoline is used as a raw material to prepare the PD-22 (51 mg, 31%). 1HNMR 400MHz(DMSO-d6 ) δ: 9.24(s, 1H), 8.08 (d, J=8.8Hz, 1H), 7.83(d, J=8.8Hz, 1H), 7.67-7.62(m, 1H), 7.34(d, J=8.0Hz, 2H), 6.99(d, J=8.0Hz,1H), 6.48(d, J=8.0Hz, 1H), 5.01(m, 1H). Embodiment 23Synthesis of PD-23
    [0055] According to the method of Embodiment 1, 2-chloro-6- (trifluoromethyl) naphthalene is used as a raw material to prepare the PD-23 (72 mg, 52%). 1HNMR 400MHz(DMSO-d6 ), 9.24(s, 1H), 8.08 (d, J=8.8Hz, 1H), 7.83(d, J=8.8Hz, 1H), 7.67-7.53(m, 2H), 7.34(d, J=8.0Hz, 2H), 6.99-6.93(m,2H), 6.43(d, J=8.0Hz,1H), 5.02(m, 1H). Embodiment 24Synthesis of PD-24
    [0056] According to the method of Embodiment 1, 2-chloro-naphthalene-5-carboxylic acid methyl ester is used as a raw material to prepare the PD-24 (57 mg, 38%). 1H NMR (400 MHz, DMSO) δ 9.15 (s, 1H), 8.81 (d, J = 9.4 Hz, 1H), 8.16 - 8.04 (m, 2H), 7.77 (d, J = 8.6 Hz, 1H), 7.64 - 7.55 (m, 2H), 7.47 (dd, J = 9.3, 2.7 Hz, 1H), 7.16 - 7.05 (m, 2H), 4.94 (s, 2H), 3.94 (s, 3H). Embodiment 25Synthesis of PD-25
    [0057] According to the method of Embodiment 1, 2-chloro-6-cyanonaphthalene is used as a raw material to prepare the PD-25 (37 mg, 28%). 1H NMR (400 MHz, DMSO) δ 9.22 (s, 1H), 8.59 (s, 1H), 8.15 (d, J = 9.0 Hz, 1H), 8.03 (d, J = 8.6 Hz, 1H), 7.84 - 7.73 (m, 2H), 7.58 - 7.46 (m, 2H), 7.20 - 7.09 (m, 2H), 4.98 (s, 2H). Embodiment 26Synthesis of PD-26
    [0058] According to the method of Embodiment 1, 2,4-dichloro-6-cyanoquinoline is used as a raw material to prepare the PD-26 (43 mg, 36%). 1HNMR 400MHz(DMSO-d6 ) δ: 9.23(s, 1H), 8.35 (d, J=9.2Hz, 1H), 7.81(d, J=8.8Hz,1H), 7.62 (d, J=8.0Hz,1H), 6.92(d, J=9.2Hz, 1H), 6.78-6.63(m,2H), 6.46 (d, J=9.2Hz, 1H), 5.04(m, 1H). Embodiment 27Synthesis of PD-27
    [0059] Referring to the method of Embodiment 1, 2,4-dichloroquinoline-6-carboxylic acid methyl ester is used as a raw material to prepare the PD-27 (63 mg, 36%). 1H NMR (400 MHz, DMSO) δ 9.34 (s, 1H), 8.91 (d, J = 1.8 Hz, 1H), 8.35 (dd, J = 8.8, 2.0 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.46 (d, J = 1.6 Hz, 1H), 7.38 (dd, J = 8.0, 2.1 Hz, 1H), 6.67 (s, 1H), 5.06 (s, 2H), 3.96 (s, 3H). Embodiment 28Synthesis of PD-28
    [0060] According to the method of Embodiment 1, 2,4-dichloro-6-trifluoromethylquinoline is used as a raw material to prepare the PD-28 (23 mg, 16%). 1HNMR 400MHz(DMSO-d6 ) δ: 9.22(s, 1H), 8.34 (d, J=9.2Hz, 1H), 7.82(d, J=8.8Hz,1H), 7.58 (d, J=8.0Hz,1H), 6.97(d, J=9.2Hz, 1H), 6.78-6.62(m,2H), 6.51 (d, J=9.2Hz, 1H), 5.04(m, 1H).
    权利要求:
    Claims (7)
    [0001] A compound having a following general formula (I) or a pharmaceutically acceptable salt thereof:
    [0002] The compound or a pharmaceutically acceptable salt thereof according to claim 1, comprising any of the following structural formulas:
    [0003] The compound or a pharmaceutically acceptable salt thereof according to claim 1, comprising any of the following formula:
    [0004] The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the pharmaceutically acceptable salt is a potassium salt, a sodium salt, an ammonium salt, a hydrochloride salt, a sulfate salt, a phosphate salt, a hydrobromide salt, a maleate salt, a fumarate salt, a citrate salt, a mesylate salt, a p-toluenesulfonate salt, a tartrate salt or an acetate salt of the compound having the general formula (I).
    [0005] A pharmaceutical composition, comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutically acceptable carrier.
    [0006] A use of the compound or a pharmaceutically acceptable salt thereof according to claim 1 for preparing a drug for inhibiting phosphodiesterase 4.
    [0007] A use of the compound or a pharmaceutically acceptable salt thereof according to claim 1 for preparing a drug for preventing or treating inflammation-related diseases.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP2018062535A|2018-04-19|Methods of treating cancer
    US9458145B2|2016-10-04|Benzimidazole derivatives as bromodomain inhibitors
    EP3152212B1|2019-12-11|Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
    RU2704112C2|2019-10-24|Fibroblast growth factor receptor inhibitors
    TWI676620B|2019-11-11|Inhibitors of lysine specific demethylase-1
    EP3092227B1|2018-07-11|Bicyclic heterocyclic derivatives as bromodomain inhibitors
    EP3290407B1|2020-01-01|Bromodomain inhibitors
    US9255089B2|2016-02-09|Benzimidazolone derivatives as bromodomain inhibitors
    EP3283077B1|2021-03-10|Bromodomain inhibitors
    Keri et al.2010|Analgesic, anti-pyretic and DNA cleavage studies of novel pyrimidine derivatives of coumarin moiety
    EP3170813B1|2018-12-12|Benzimidazole derivatives as pi3 kinase inhibitors
    EP2493862B1|2016-10-05|Imidazole derivatives as ido inhibitors
    EP1458392B9|2010-07-28|Acridones as inhibitors of impdh enzyme
    ES2614355T3|2017-05-30|N-substituted glycine derivatives with pyridazine dione as HIF hidoxylase inhibitors
    JP5658664B2|2015-01-28|1,2-disubstituted heterocyclic compounds
    EP2464232B1|2015-10-07|Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
    AP866A|2000-08-17|Benzimidazole compounds.
    RU2285693C2|2006-10-20|Derivatives of pyridine and quinoline, method for their preparing, pharmaceutical composition, using compounds for treatment of dpp-iv-associated diseases
    EP3194375B1|2018-11-21|Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
    DE60012044T2|2005-07-07|Imidazopyridine derivatives as ligands for GABA receptors
    RU2434871C2|2011-11-27|Pyrrolopyrimidines used as protein kinase inhibitors
    EP1067123B1|2011-01-19|Nitrogenous heterocyclic compounds
    CN101754962B|2013-12-25|N-azacyclic substituted pyrrole, imidazole, triazole and tetrazole derivatives as agonists of RUP3 or GPR119 for treatment of diabetes and metabolic disorders
    EP1556055B1|2008-10-29|Cyclic nucleotide phosphodiesterase inhibitors having a benzodiazepine structure and their use in therapy
    EP3632910A1|2020-04-08|Lactam compound as fxr receptor agonist
    同族专利:
    公开号 | 公开日
    EP3708568A4|2020-10-21|
    JP2021503507A|2021-02-12|
    CN108148085B|2019-11-01|
    WO2019134556A1|2019-07-11|
    CN108148085A|2018-06-12|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2019-07-12| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
    2020-08-14| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
    2020-08-14| PUAI| Public reference made under article 153(3) epc to a published international application that has entered the european phase|Free format text: ORIGINAL CODE: 0009012 |
    2020-09-16| AX| Request for extension of the european patent|Extension state: BA ME |
    2020-09-16| AK| Designated contracting states|Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2020-09-16| 17P| Request for examination filed|Effective date: 20200420 |
    2020-10-21| RIC1| Information provided on ipc code assigned before grant|Ipc: A61K 31/69 20060101ALI20200915BHEP Ipc: C07F5/02 20060101AFI20200915BHEP Ipc: A61P 29/00 20060101ALI20200915BHEP |
    2020-10-21| A4| Supplementary search report drawn up and despatched|Effective date: 20200921 |
    2021-04-07| DAX| Request for extension of the european patent (deleted)|
    2021-04-07| DAV| Request for validation of the european patent (deleted)|
    2021-08-26| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: GRANT OF PATENT IS INTENDED |
    2021-08-26| GRAP| Despatch of communication of intention to grant a patent|Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
    2021-09-22| INTG| Intention to grant announced|Effective date: 20210827 |
    2021-12-16| GRAS| Grant fee paid|Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
    2022-01-07| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
    2022-01-07| GRAA| (expected) grant|Free format text: ORIGINAL CODE: 0009210 |
    2022-02-09| AK| Designated contracting states|Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2022-02-09| REG| Reference to a national code|Ref country code: GB Ref legal event code: FG4D |
    2022-02-15| REG| Reference to a national code|Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1467466 Country of ref document: AT Kind code of ref document: T Effective date: 20220215 |
    2022-03-03| REG| Reference to a national code|Ref country code: DE Ref legal event code: R096 Ref document number: 602018030766 Country of ref document: DE |
    优先权:
    申请号 | 申请日 | 专利标题
    [返回顶部]